Vusion Patent Expiration

Vusion is a drug owned by Mylan Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 30, 2028. Details of Vusion's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8147852 Modified azole compounds as antifungal and antibacterial agents
Mar, 2028

(3 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vusion's patents.

Given below is the list of recent legal activities going on the following patents of Vusion.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 19 Sep, 2023 US8147852
Change in Power of Attorney (May Include Associate POA) 16 May, 2022 US8147852
Email Notification 16 May, 2022 US8147852
Correspondence Address Change 13 May, 2022 US8147852
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 26 Sep, 2019 US8147852
Payment of Maintenance Fee, 8th Year, Large Entity 26 Sep, 2019 US8147852
Change in Power of Attorney (May Include Associate POA) 14 Nov, 2016 US8147852
Email Notification 14 Nov, 2016 US8147852
Correspondence Address Change 10 Nov, 2016 US8147852
Change in Power of Attorney (May Include Associate POA) 06 May, 2016 US8147852


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Vusion and ongoing litigations to help you estimate the early arrival of Vusion generic.

Vusion's Litigations

Vusion been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 15, 2010, against patent number US8147852. The petitioner , challenged the validity of this patent, with Marcel Borgers et al as the respondent. Click below to track the latest information on how companies are challenging Vusion's patents.

Last updated on October 8, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8147852 November, 2010 Decision
(08 Aug, 2011)
Marcel Borgers et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Vusion is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vusion's family patents as well as insights into ongoing legal events on those patents.

Vusion's Family Patents

Vusion has patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click below to unlock the full patent family tree for Vusion.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Vusion's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 30, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Vusion Generics:

There are no approved generic versions for Vusion as of now.





About Vusion

Vusion is a drug owned by Mylan Pharmaceuticals Inc. It is used for treating diaper dermatitis complicated by candidiasis. Vusion uses Miconazole Nitrate; White Petrolatum; Zinc Oxide as an active ingredient. Vusion was launched by Mylan in 2006.

Approval Date:

Vusion was approved by FDA for market use on 16 February, 2006.

Active Ingredient:

Vusion uses Miconazole Nitrate; White Petrolatum; Zinc Oxide as the active ingredient. Check out other Drugs and Companies using Miconazole Nitrate; White Petrolatum; Zinc Oxide ingredient

Treatment:

Vusion is used for treating diaper dermatitis complicated by candidiasis.

Dosage:

Vusion is available in ointment form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.25%;81.35%;15% OINTMENT Prescription TOPICAL